KRAS and MAPK1 gene amplification in type II ovarian carcinomas. - Wikidata - wikimedia - TriplyDB

KRAS and MAPK1 gene amplification in type II ovarian carcinomas.

KRAS and MAPK1 gene amplification in type II ovarian carcinomas.

http://www.wikidata.org/entity/Q37091859

about

Single Synonymous Mutations in KRAS Cause Transformed Phenotypes in NIH3T3 Cells MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.KRAS mutation coupled with p53 loss is sufficient to induce ovarian carcinosarcomas in mice.Influence of node abundance on signaling network state and dynamics analyzed by mass cytometry.Actionable gene-based classification toward precision medicine in gastric cancer.

P2860

Q27321600-20EBF3C2-2E88-4044-B059-3A1D45B39FF1 Q34584317-596B7DEB-918D-44BF-AD1B-107F3C3992F3 Q38723863-5847EF69-73E9-4143-907A-1C784A13ADAC Q39018181-379F7523-889E-4953-9342-D346C5514C06 Q47113548-088B1670-4FCD-4B6E-AA03-43B6326DD237

P2860

KRAS and MAPK1 gene amplification in type II ovarian carcinomas.

http://www.wikidata.org/entity/Q37091859

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 July 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

KRAS and MAPK1 gene amplification in type II ovarian carcinomas.

@en

KRAS and MAPK1 gene amplification in type II ovarian carcinomas.

@nl

type

label

KRAS and MAPK1 gene amplification in type II ovarian carcinomas.

@en

KRAS and MAPK1 gene amplification in type II ovarian carcinomas.

@nl

prefLabel

KRAS and MAPK1 gene amplification in type II ovarian carcinomas.

@en

KRAS and MAPK1 gene amplification in type II ovarian carcinomas.

@nl

P1433

Q37091859-A53210E0-1DFB-4368-BCC7-19620D5D31EF

P1476

Q37091859-14D99876-570B-49E6-B10E-211E4D73EA72

P2093

Q37091859-0923588C-DC8B-4EFA-B7C5-4BF9962B3061

Q37091859-0BF1FE09-D439-4D00-9885-C4D0A771373A

Q37091859-1423F7BE-C16D-402B-8B89-397888846F72

Q37091859-24F50A13-10B8-4A66-968D-B911B52B1D8A

Q37091859-2EA71514-FA96-473F-9F8B-F43CB56D773E

Q37091859-4556082C-E4BA-4762-BC41-7C4D2476718B

Q37091859-618BB591-4E51-4C69-B4E0-F8948A536DA1

Q37091859-73BD6FB8-D6DC-4B88-8E29-53D5286C3E1B

Q37091859-7E9C6849-01A2-4004-853B-9D378AED8FFA

Q37091859-86917079-C17B-411E-A954-A11345C2C71D

P2860

Q37091859-021B8EAB-A279-4AE7-89AF-D70B678440D2

Q37091859-134B889E-ADD2-424D-AC5A-1627D1DEC88B

Q37091859-20531F7A-443F-4448-BBB6-56D682B9239F

Q37091859-2B543A02-4967-42A8-B62B-2187F2810A50

Q37091859-3D22DE86-5C08-4E38-942C-3540B02BA27F

Q37091859-3F7AD89A-1F06-4ABA-8D2F-BE282F49C3D5

Q37091859-43F3FCA3-9F11-449E-9550-718BB18C81B2

Q37091859-5CF4B649-3FD2-46AE-B9F6-540FBA03526D

Q37091859-60D86DFE-C532-4FFD-B996-78D6BEFD4B30

Q37091859-6ABD0116-00B0-4FCB-ABAB-9361CD9BA599

P304

Q37091859-28C44662-14F4-40BF-8D73-FB80A99E0534

P31

Q37091859-25B74F18-8B3E-4C3C-91ED-B65A9697F9ED

P356

Q37091859-A4240857-E66A-46C3-8BEB-A19EE507FD79

P407

Q37091859-A6C59D4B-4D01-471B-9AD2-89532A413476

P433

Q37091859-7EC73DD7-D16A-427C-9446-EB989E094D8E

P478

Q37091859-2AA8FDD0-8E52-4C14-B689-37622E033DE1

P577

Q37091859-3ED6726C-5CC0-48D4-A27C-11CFADD7BA0D

P5875

Q37091859-2D71F884-149A-4CE5-AB4F-FF3D32C771D1

P698

Q37091859-D9CBD66A-07EB-4E21-B528-18671AB59040

P932

Q37091859-EEAF0487-8600-453C-8483-6383BE8CF61E

P356

P1433

International Journal of Molecular Sciences

P1476

KRAS and MAPK1 gene amplification in type II ovarian carcinomas.

@en

P2093

Atsuko Katagiri

http://www.w3.org/2001/XMLSchema#string

Emi Sato

http://www.w3.org/2001/XMLSchema#string

Hiroshi Katagiri

http://www.w3.org/2001/XMLSchema#string

Kentaro Nakayama

http://www.w3.org/2001/XMLSchema#string

Kohji Miyazaki

http://www.w3.org/2001/XMLSchema#string

Kouji Iida

http://www.w3.org/2001/XMLSchema#string

Masako Ishikawa

http://www.w3.org/2001/XMLSchema#string

Mohammed Tanjimur Rahman

http://www.w3.org/2001/XMLSchema#string

Munmun Rahman

http://www.w3.org/2001/XMLSchema#string

Naomi Nakayama

http://www.w3.org/2001/XMLSchema#string

P2860

Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.

EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target.

Integrated genomic analyses of ovarian carcinoma

Mutations of the BRAF gene in human cancer

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels.

Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer.

Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.

Prognostic and predictive factors.

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer

P304

13748-13762

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/IJMS140713748

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

244991742

http://www.w3.org/2001/XMLSchema#string

P698

23820584

http://www.w3.org/2001/XMLSchema#string

P932

3742215

http://www.w3.org/2001/XMLSchema#string